Stem-Cell Clinical Trials Move Debate Beyond Labs

Next year, Pfizer and a clutch of British scientists hope to join a small group of researchers conducting the first clinical trials in one of the more contentious areas of science: medical treatments derived from human embryonic stem cells.

The Tough Business of Caring

Pharma companies find themselves unfairly labeled bad guys as they try to resist being strong-armed into lowering prices by cash-strapped governments. Lars Rebien Sorensen, chief executive of Novo Nordisk, weighs in.

FDA Approves Merck Diabetes-Cholesterol Drug

The U.S. Food and Drug Administration Friday approved the first combination product to treat type 2 diabetes and high cholesterol in one tablet. The combination product will be sold as Juvisync by Merck.

Panel Faults Prostate-Cancer Test

A key federal advisory panel is poised to recommend that healthy men shouldn't be screened with the widely used PSA test for prostate cancer, indicating that the test offers more harm than benefit.

• Read: The review behind the panel's recommendation

Drug Maker's Ploy to Delay Generics: Add a Line to Pill

Congressman Investigates High Drug Markups

Japanese Buying Spree Continues

Merck Leadership Transition Set

Pfizer Halts Lyrica Epilepsy Study